3CC | Third Culture Capital

What 3CC | Third Culture Capital does

Third Culture Capital (3CC) is a Boston-based, immigrant-founded, physician-led, diversity-certified seed-stage venture capital firm established in 2020. The firm invests at the intersection of healthcare, technology, and access, targeting early-stage healthtech and techbio companies whose founders have converted outsider status into a competitive edge. Its investment thesis is delivered to the market through a productized platform spanning Simplify (thesis and founder philosophy), Amplify (investor and founder portal), Portfolio (investment showcase), Thought Repository (newsletters, interviews, fund thinking), and Team.

3CC employs a conventional venture fund revenue model consisting of management fees charged to limited partners, carried interest on profitable exits (typically 20% above the hurdle), and investment returns from equity stakes in portfolio companies. Distribution is global in scope, with deal access and fund information made available through the Amplify platform and direct inbound via a website contact form. Marketing and LP development are content-driven — a healthcare innovation newsletter, the Thought Repository, and a stated 24-48 hour response window for inquiries.

Operationally, 3CC runs lean at 1-10 employees under founder and managing partner Julien L. Pham, MD, MPH. The firm differentiates on sourcing rather than technology: it pursues founders from third-culture, immigrant, and physician backgrounds who are systematically under-networked by mainstream capital. The input does not disclose fund size, AUM, LP composition, portfolio companies, or investment track record — these are material gaps for any diligence process.

Name

3CC | Third Culture Capital

Legal name

Third Culture Capital

Website

https://3cc.io

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Third Culture Capital (3CC) is a Boston-based, immigrant-founded, physician-led seed-stage venture capital firm investing in healthtech and techbio startups led by outsider founders, operating from 1-10 employees with management fees and carried interest as its revenue model.

Ownership category

akta.pro rank

Product category

Seed-Stage Venture Capital

NAICS

Other Financial Investment Activities (5239), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Geography-Focused Venture Capital (Regional/Emerging Markets) (FSANAAAE)

Keywords

• Seed-stage venture capital
• Healthtech venture investing
• Techbio early-stage funding
• Immigrant founder backing
• Outsider founder capital

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Investment Returns: Returns generated from equity investments in portfolio companies through exits, acquisitions, or IPOs.
2. Management Fees: Recurring fees charged to fund limited partners for managing the venture capital fund.
3. Carried Interest: Performance-based share of profits from successful portfolio company exits, typically 20% of returns above the hurdle rate.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Third Culture Capital is a seed-stage venture capital firm that invests in early-stage healthtech and techbio companies founded by outsider, immigrant, and underrepresented entrepreneurs operating at the intersection of healthcare, technology, and access. Beyond capital deployment, the firm curates educational content (Thought Repository), portfolio information, and investor/founder resources through its Amplify platform to support portfolio companies and attract limited partners.

Product overview

Third Culture Capital (3CC) is a venture capital firm that operates as a single unified investment fund focused on healthcare, technology, and access. The fund is organized into three interconnected service areas: Simplify (articulating the investment thesis, fund story, and founder philosophy), Amplify (providing comprehensive information for investors and founders), and Portfolio (showcasing investment outcomes and early-stage conviction investments). These offerings collectively form the fund's investment platform without distinct product modules or standalone commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

• Third Culture Capital Seed Venture Fund Seed-stage venture capital investment fund providing capital and strategic support to early-stage companies founded by outsider, immigrant, and underrepresented entrepreneurs at the intersection of healthcare, technology, and access. The fund targets seed-stage healthtech and techbio companies.
• Amplify Investor and Founder Information Platform Information resource providing qualified investors and founders with the complete picture of the fund, including investment strategy and partnership opportunities. Available through the Amplify section of the website.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Expansion highlights3 records

Emerging players

• Petri: Seed-stage fund focused on founders building at the intersection of science and technology, closely mirroring 3CC's techbio/healthtech seed thesis with comparable fund size and emerging-manager profile.
• Operator Partners: Early-stage fund led by operators backing technical founders, comparable to 3CC in stage and emerging-manager profile though with less of a healthtech-specific focus.

Direct peers

• Civilization Ventures: Early-stage investor in health, technology, and biology startups, with a comparable emerging-manager profile and a focus similar to 3CC's healthcare-technology-access intersection thesis.
• KdT Ventures: Seed-stage fund investing in techbio companies at the intersection of technology and biology, serving as a direct comparable to 3CC's healthtech/techbio seed focus.
• Flare Capital Partners: Healthcare-focused early-stage VC backing digital health and healthtech founders, comparable to 3CC in thesis and stage though typically with larger fund vintages.
• Healthy Ventures: Seed-stage investor focused on healthcare and digital health startups, aligning with 3CC's early-stage healthtech orientation and emerging-manager profile.

Broad incumbents

• ARCH Venture Partners: Large, established venture firm investing across biotech, healthtech, and technology, representing a broad incumbent comparable to 3CC's sector overlap but at materially greater scale.
• Lux Capital: Tech-and-science-focused venture firm with substantial health and bio investing, providing a broad-incumbent benchmark for 3CC's healthcare-technology convergence thesis.
• Andreessen Horowitz (a16z Bio + Health): Major venture platform with dedicated bio/health funds investing across healthcare and techbio, an incumbent comparable to 3CC on sector overlap though vastly larger in scale and brand.
• New Enterprise Associates (NEA): Large multi-stage firm with extensive healthtech and biotech exposure, serving as a broad-incumbent peer for 3CC's sector-focused investing approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/thirdculturecap
• LinkedInlinkedin.com/company/thirdculturecapital

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3CC | Third Culture Capital